Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Chemotherapy and Cetuximab/Bevacizumab in Potentially Resectable Colorectal Cancer With Liver Metastases
NCT07863869Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2026
- Primary completion
- May 2029
01
Overview
Phase 2, open-label trial of QL1706 in colorectal cancer (CRC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: 18-month Progression-Free Survival rate and Safety at 18 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07863869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863869.